Table 2

Mean change in BCVA after 12 months’ treatment with anti-VEGF therapy

Drug	Study	Design	Total sample size (patients)	Patients receiving anti-VEGF treatment	Mean change in BCVA (ETDRS letters)	Injection number over 12 months (mean)	OCEBM level of evidence55
Ranibizumab	RADIANCE52	Phase III, randomised, double masked, active controlled, multicentre	277	106*	13.8	4.6	2
	RADIANCE52		277	116†	14.4	3.5	2
	REPAIR53	Phase II, prospective, open label, multicentre	65	65	13.8	3.6	4
	Franqueira et al 201257	Retrospective case series	39	39	4.3	4.1	4
	Monés et al 200959	Prospective case series	23	23	9.5	1.5	4
	Silva et al 201060	Prospective case series, multicentre	32	32	8	3.6	4
	Lai et al 200962	Retrospective case series	16	16	15‡	3.8	4
Bevacizumab	Ikuno et al 200964	Retrospective case series	63	63	11.5‡	2.4	4
	Chan et al 200965	Prospective case series	29	29	12‡	3.6	4
	Gharbiya et al 200966	Prospective case series	20	20	18.2	4.0	4
	Ruiz-Moreno et al 201167	Prospective, comparative, non-randomised multicentre	38	18§	6.3	3.2	4
	Ruiz-Moreno et al 201167	Prospective, comparative, non-randomised multicentre	38	20¶	7.2	1.7	4
	Ruiz-Moreno et al 201068	Retrospective case series, multicentre	107	107	8.7	1††	4
	Ruiz-Moreno et al 2011, 201369 70	Prospective, randomised, multicentre	55	25	11.2	3.5	3
	Iacono et al 201171	Prospective case series	30	30	3.8	4.7	4
	Gharbiya et al 201272	Prospective case series	30	30	16.4	4.1	4
	Hayashi et al 201273	Prospective case series	69	69	10.5‡	NR‡‡	4
	Hayashi et al 200974	Prospective case series	156	43	11.5‡	1.6	4

OCEBM levels of evidence grades are as follows: 1: systematic review of randomised trials; 2: randomised trial; 3: non-randomised controlled cohort/follow-up study; 4: case series, case control, or historical controlled study; 5: mechanism-based reasoning.
*Retreatment according to visual acuity stabilisation criteria.
†Retreatment according to disease activity criteria.
‡Approximate ETDRS changes, based on reported logMAR values.
§Patients received three monthly loading doses.
¶Patients received one loading dose.
††For 60% of patients.
‡‡1.8 injections over 2 years.
BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; logMAR, logarithm of the minimum angle of resolution; OCEBM, Oxford Centre for Evidence-Based Medicine; NR, not reported; VEGF, vascular endothelial growth factor.